WO2005105128A1 - 霊芝処理物および霊芝加工品の製造方法 - Google Patents
霊芝処理物および霊芝加工品の製造方法 Download PDFInfo
- Publication number
- WO2005105128A1 WO2005105128A1 PCT/JP2005/007810 JP2005007810W WO2005105128A1 WO 2005105128 A1 WO2005105128 A1 WO 2005105128A1 JP 2005007810 W JP2005007810 W JP 2005007810W WO 2005105128 A1 WO2005105128 A1 WO 2005105128A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reishi
- processed
- product
- ganoderma lucidum
- water
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
Definitions
- the present invention relates to a method for producing a processed reishi product or a processed product of a reishi product, a food and beverage containing the same, and a pharmaceutical product.
- a hot water extract of mushrooms has long been described and conveyed various medicinal effects. In particular, it was known in China and Japan that mushrooms are effective against cancer. This has been scientifically verified and reported. For example, in Non-Patent Document 1, a hot-water extract of edible mushrooms showed a host-mediated antitumor activity against Sarcoma 180 tumor-bearing mice. 'It is disclosed that there is sex!
- Reishi is a power that usually uses an extract obtained by extraction with hot water at 100 ° C or lower. This method has a very low extraction efficiency, and in recent years, a method to increase the extraction efficiency has been developed. It has been.
- Patent Document 1 describes that Ganoderma lucidum is extracted with hot water under pressure and then subjected to a saturated steam heating treatment, and it is described that such treatment improves the extraction rate of Ganoderma lucidum extract. ing.
- Patent Document 2 describes that the obtained extract has a NK activity-improving effect by subjecting Ganoderma lucidum to a pressurized hot water treatment. It is described that an extract having active oxygen scavenging activity can be obtained by performing steam pressure treatment. Further, Patent Document 3 discloses that the amount of ⁇ -glucan extracted can be increased by sonicating a mushroom and then performing an enzyme treatment using cellulase or protease.
- Patent Documents 1 to 3 described above the antitumor effect has not been sufficiently confirmed, and a simple processing technology for Reishi to obtain a composition exhibiting high V ⁇ antitumor activity. It was not yet studied.
- Patent Document 1 JP-A-11 196818
- Patent Document 2 Japanese Patent Application Laid-Open No. 2001-187745
- Patent Document 3 Japanese Patent Application Laid-Open No. 2002-262820
- Non-patent literature l Jpn.J. Cancer Res., 59, 155, 1968
- Non-Patent Document 2 Agric. Biol. Chem., 49, 2641, 1985
- the present invention provides
- a method for producing a processed product of Ganoderma lucidum comprising treating Ganoderma lucidum with steam at 150 to 210 ° C.
- Reishi is treated with steam at 150-210 ° C, and the resulting Reishi is processed.
- a method for producing a processed Reishi product comprising extracting Reishi with water at 150 to 210 ° C, or further concentrating the dried extract or drying the water extract.
- a processed reishi product or a processed reishi product having an excellent antitumor effect can be produced in an industrially advantageous manner with improved extraction efficiency. Further, according to the present invention, foods and drinks and pharmaceuticals containing the reishi processed product and the processed reishi product having excellent antitumor activity can be provided.
- FIG. 1 shows a measurement result of an extraction rate in Test Example 3.
- FIG. 2 shows the
- Reishi used in the present invention is Ganoderma lucidum (Ganoderma lucidum).
- the whole fruit body of Ganoderma lucidum may be used entirely, or a part of the fruiting body (for example, an appropriately cut body of Ganoderma lucidum) may be used.
- the reishi is usually treated with water or an organic solvent or the like, and in the present invention, it is preferable that the reishi is not exposed to water until the reishi is subjected to the steam treatment. Good.
- One embodiment of the present invention is to treat Ganoderma lucidum with steam at 150 to 210 ° C to produce a processed Ganoderma lucidum.
- saturated steam is preferred as the steam used for the treatment of ganoderma, but is not limited thereto.
- the processing conditions are not particularly limited as long as the temperature of the steam is 150 to 210 ° C. In the present invention, it is preferable that the temperature range is 170 to 210 ° C.
- Particularly preferred is 0 ° C.
- the water vapor temperature is lower than 150 ° C, the effect of increasing the active ingredient having an antitumor effect is small, and when the temperature is higher than 210 ° C, the effect of increasing the active ingredient is small.
- the treatment time is not particularly limited as long as the object of the present invention is not hindered, but is usually about 1 to 30 minutes.
- the higher the steam temperature the shorter the treatment time.
- the steam temperature is 200 ° C, 3 to 10 minutes is desirable.
- the oxygen concentration in the treatment is not particularly limited. However, if the amount of oxygen is large, an organic acid or furfural is generated by oxidative decomposition, which may affect the flavor. It is preferable that the element concentration is low. For example, it is desirable to set the oxygen concentration to O 1 / z gZml.
- the above treatment can be performed under normal pressure, but is generally preferably performed under pressure.
- the pressurizing pressure is not particularly limited, but when using saturated steam as steam, the pressurizing pressure is usually from 0.3 to 1.8 MPa.
- the steam treatment may be performed using a known treatment device.
- the treatment apparatus is not particularly limited as long as it can perform steam treatment at 150 to 210 ° C.
- a high-temperature high-pressure reactor manufactured by AKICO or a high-temperature moist heat treatment test apparatus manufactured by Hisaka Seisakusho Co., Ltd. (HTS-257140-8039), a superheated steam generator (DPH GH20) manufactured by Seta Kosan Kako Co., Ltd.
- DPH GH20 superheated steam generator
- a processed Reishi product is produced by subjecting the processed Reishi product obtained as described above to further known processing.
- the processed Reishi product obtained as described above is produced by subjecting the processed Reishi product obtained as described above to further known processing.
- a processed Reishi product can be manufactured by drying and then shearing or pulverizing the processed Reishi product. .
- the extraction operation can be performed according to a conventional method if the extraction temperature, time, and apparatus are appropriately selected.
- the aqueous solvent used as the extraction solvent in the treatment 2) include a solvent containing water or water.
- hot water extraction may be performed at, for example, 120 ° C. using an autoclave.
- a concentrated extract can be obtained by removing the solvent of the extract obtained by the treatment of the above 2).
- the extract is dried by freeze-drying or air-drying to obtain a dry powder product. can do.
- the extract obtained by the above treatment 2) may be diluted with a solvent such as water.
- One embodiment of the present invention is to produce a processed product of Ganoderma lucidum by extracting Ganoderma lucidum with water at 150 to 210 ° C.
- the water used for the extraction of Reishi is preferably high-temperature and high-pressure water.
- the treatment conditions are not particularly limited as long as the temperature of the water is 150 to 210 ° C.
- the temperature is preferably 180 to 210 ° C. in the above temperature range. If the temperature of water is less than 150 ° C, the effect of increasing the active ingredient for antitumor effect is small, and if it is higher than 210 ° C, the effect of increasing the active ingredient is small or decreased. ,.
- the treatment time is not particularly limited as long as the object of the present invention is not hindered, but is usually about 1 to 30 minutes. Generally, the higher the temperature of water, the shorter the treatment time. For example, when the temperature of water is 200 ° C., 3 to 10 minutes is desirable.
- the oxygen concentration in the treatment is not particularly limited. However, since the amount of oxygen is high and organic acids and furfural are generated by oxidative decomposition, and the flavor may be affected, the oxygen concentration may be reduced. Is preferably lower. For example, it is desirable to set the oxygen concentration to O 1 / z gZml.
- the treatment can be performed under normal pressure, but is generally preferably performed under pressure.
- the pressure is not particularly limited, but the pressure is usually 0.3 to 1.8 MPa.
- the water treatment may be performed using a known treatment device.
- the treatment apparatus is not particularly limited as long as it can perform water extraction at a high temperature and high pressure of 150 to 210 ° C.
- a high temperature and high pressure reactor manufactured by AKICO and a high temperature high pressure reactor manufactured by Hisaka Manufacturing Co., Ltd.
- a moist heat treatment test device (HTS 25/140 8039), a superheated steam generator (DPH G H20) manufactured by Seta Kosan Kako Co., Ltd., or the like can be used.
- the extract extracted with high-temperature and high-pressure water in the above-mentioned manner can be used as a processed product of Reishi.
- the processed reishi product obtained as described above can be further subjected to a known treatment.
- concentrated extract can be obtained by removing the solvent of the extract.
- the extract may be dried by freeze-drying or air-drying to obtain a dry powder product.
- you may dilute with a solvent, such as water.
- One embodiment of the present invention is to treat Ganoderma lucidus with steam at 150 to 210 ° C to produce a processed Ganoderma lucidum.
- the thus-obtained reishi product or the reishi product contains a high content of water-soluble j8-glucan which is known to have an antitumor effect.
- water-soluble j8-glucan with a strength of 100 g or less and a power of less than 100 lg cannot be extracted, whereas the water vapor treatment or high-temperature high-pressure water treatment of the present invention should be performed.
- 0.5 to 5 g of water-soluble j8-glucan can be provided per 100 g of raw material Reishi.
- Another embodiment of the present invention is also a food and drink and a pharmaceutical containing the above-mentioned processed Ganoderma lucidum or the above processed Ganoderma lucidum.
- These foods and drinks and pharmaceuticals are manufactured from the above-mentioned processed Ganoderma lucidum or the above processed Ganoderma lucidum using known means. Since the above-mentioned processed product of reishi and the processed product of reishi are excellent in safety, special treatment for obtaining safety is usually not required.
- the blending amount of the above-mentioned reishi-treated product and the above-mentioned reishi-treated product in the food and drink and the pharmaceutical product of the present invention is appropriately determined in consideration of the effect thereof, the fragrance of the product when added, the color tone, and the like. Can be.
- the above-mentioned processed product of Ganoderma lucidum or the processed product of Ganoderma lucidum described above is converted to a dry weight, which is usually 0. It is desirably in the range of 01 to 99.9% by mass, preferably 0.01 to 99.5% by mass.
- Examples of the food and drink include candy, troche, gum, yogurt, ice cream, pudding, jelly, mizukan, alcoholic drink, tea drink, coffee drink, juice, fruit drink, carbonic drink, soft drink, Examples include various kinds of milk, whey drinks, lactic acid drinks, and the like.
- the food or drink can be produced according to a conventional method by blending the above-mentioned processed Ganoderma lucidum or the processed Ganoderma lucidum and various additives as necessary.
- Additives that may be added as needed include, for example, glucose, fructose, sucrose, maltose, sorbitol, stepioside, rubusoside, corn syrup, lactose, citrate, tartaric acid, malic acid, succinic acid, lactic acid, L- Ascorbic acid, dl-a-tocopherol, sodium erysorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, arabia gum, carrageenan, casein Examples thereof include those used as ordinary food ingredients such as gelatin, pectin, agar, vitamin Bs, nicot
- the food or drink may be a health food!
- the shape of the health food is not particularly limited, and may be in the form of granules, capsules, pills, tablets, chewables, extracts, pastes, beverages, and the like. Alternatively, it may be in a form extracted with hot water or the like, such as tea.
- an intended health food can be prepared by incorporating an appropriate amount of the above-mentioned reishi treated product or the above-mentioned reishi product according to a conventional method.
- the above-mentioned processed Ganoderma lucidum or processed Ganoderma lucidum and if desired, fats and oils such as vegetable oils, waxes such as lanolin and beeswax, hydrocarbons, fatty acids, higher alcohols, esters, Various pigments, fragrances, vitamins, plant 'animal extract components, antioxidants, antiseptic', etc., which are used as normal health food raw materials, such as biocides, are appropriately blended, and health foods are formulated according to ordinary methods. Can be obtained.
- the food or drink of the present invention can be labeled to have an effect known as the efficacy of j8-glucan, for example, an antitumor effect, immunostimulatory effect or anticancer effect of j8.
- the indication place may be a container or an instruction attached thereto. Display methods include, but are not limited to, printing, engraving, sealing, and the like.
- the food and drink of the present invention are suitably used as so-called health foods and health functional foods, since both the above-mentioned processed products of Ganoderma lucidum and processed Ganoderma lucidum have good antitumor activity.
- it is suitably used as a food or drink having an antitumor effect.
- the pharmaceutical product of the present invention is prepared as a pharmaceutical product in various dosage forms by blending the above-mentioned processed product of Ganoderma lucidum or the above processed Ganoderma lucidum and various additives as necessary, and further containing an appropriate amount of the processed product of Ganoderma lucidum. can do.
- Examples of the form of the above pharmaceuticals include oral pharmaceuticals such as tablets, capsules, granules, powders, syrups, and extracts, or ointments, eye ointments, lotions, creams, patches, and suppositories.
- Parenteral pharmaceuticals such as preparations, eye drops, nasal drops and injections.
- These pharmaceuticals may be produced according to a conventional method using the above-mentioned processed Ganoderma lucidum or processed Ganoderma lucidum and various additives as required.
- additives can be used as additives.
- solid carriers such as starch, lactose, sucrose, mannitol, carboxymethylcellulose, corn starch, and inorganic salts; distilled water, physiological saline, Glucose aqueous solution, alcohols such as ethanol, liquid carriers such as propylene glycol, polyethylene glycol and the like; various animal and vegetable oils, and oily carriers such as white petrolatum, paraffin, and waxes.
- the daily use amount and dose amount of the above-mentioned processed Ganoderma lucidum and processed Ganoderma lucidum are not particularly limited, and are, for example, a force that can be reduced to about 0.1 Olmg to LOOg in terms of dry weight, particularly oral.
- a remarkable antitumor effect is expected from the above, for example, it is preferable to be 0.1 lg to 20 g in dry weight conversion.
- the foods and drinks (especially health foods) and pharmaceuticals of the present invention include other foods and drinks having an antitumor activity, raw materials for health foods and pharmaceuticals, for example, mushrooms such as agaritas, maitake and meshimakobu, ⁇ -glucan and the like. It may be used in combination with a microorganism containing an anticancer polysaccharide or a fermentation product thereof.
- a bioreaction modifier (BRM) such as krestin
- a chemotherapeutic agent such as cyclophosphamide
- a drug for ivy may be used in combination.
- the mixing ratio is not particularly limited as long as it is appropriately set according to the purpose.
- the pharmaceutical product of the present invention is suitably used as an antitumor agent because the above-mentioned processed Ganoderma lucidum and processed Ganoderma lucidum each have a good antitumor action. Further, since it is excellent in safety when taken orally, it can be suitably used as an oral drug.
- Kazuno Reishi (commercially available, produced in Shandong, China) was used as a raw material.
- a high temperature and high pressure reactor manufactured by AKICO was used for the high temperature and high pressure treatment.
- a SUS316 alloy heat-resistant pressure vessel 400 ml was charged with 40 ml of water from which dissolved oxygen had been removed by bubbling nitrogen gas.
- 10g of Kazuno Reishi on a 200ml basket made of SUS 316 alloy 1 A piece cut into a cm piece was placed, and this was placed in a heat-resistant and pressure-resistant container made of SUS316 alloy so as not to come in contact with water.
- steam treatment was performed for 5 minutes under the conditions of saturated steam at 150 ° C, a pressure of 0.38 MPa, and an oxygen concentration of 0.95 gZml. Then, the vessel was cooled, and when the temperature of the reaction vessel reached 80 ° C., the vessel was opened, and the processed product of Kazuno Reishi was taken out.
- a Kazuno Reishi extract (reishi processed product) was obtained in the same manner as in Example 11 except that the steam treatment conditions were saturated steam at 180 ° C, 0.85 MPa, and an oxygen concentration of 0.95 ⁇ g / ml. Was.
- a Kazuno Reishi extract (reishi processed product) was obtained in the same manner as in Example 11 except that the steam treatment conditions were 200 ° C saturated steam, 1.4 MPa, and an oxygen concentration of 0.95 / z gZml. .
- Kazuno Reishi extract was obtained in the same manner as in Example 1-1, except that the steam treatment conditions were saturated steam at 220 ° C, 2.2 MPa, and an oxygen concentration of 0.95 / z gZml.
- Kazuno Reishi extract was obtained in the same manner as in Example 1-1, except that the steam treatment conditions were saturated steam at 250 ° C., 4.5 MPa, and an oxygen concentration of 0.95 / z gZml.
- Kazuno Reishi was placed in a pressure bottle, then 1 L of water was added, and extraction was performed at 121 ° C for 30 minutes (autoclave extraction) to obtain Kazuno Reishi extract.
- MM46 breast cancer cells were subcutaneously inoculated in the inguinal region of C3H mice (Nippon Charles Riva Co., Ltd.) at 2 x 10 6 cells, and the resulting mice (hereinafter also referred to as MM46 tumor-bearing mice) were inoculated. Used as subject.
- Kazuno Reishi (commercially available, produced in Shandong, China) was used as a raw material.
- a SUS316 alloy heat and pressure resistant container 400 ml was charged with 230 ml of water from which dissolved oxygen was removed to a concentration of 0.95 / z gZml or less by bubbling nitrogen gas.
- a 200 ml basket made of SUS316 alloy was filled with 10 g of Kazuno Reishi cut into lcm pieces, and placed in a heat-resistant pressure vessel made of SUS316 alloy. After the air in the container was replaced by sending nitrogen for about 5 seconds, the temperature was maintained at 150 ° C and the pressure was 0.38 MPa, and the treatment was performed for 5 minutes. Then, the vessel was cooled, and when the temperature of the reaction vessel reached 80 ° C, the vessel was opened and the Kazuno Reishi extract was recovered. This was freeze-dried to obtain a processed Reishi product (freeze-dried product).
- Kazuno Reishi extract was obtained in the same manner as in Example 2-1 except that the treatment conditions were 180 ° C saturated steam and 0.85 MPa. This was freeze-dried to obtain a processed reishi product (freeze-dried product).
- Kazuno Reishi extract was obtained in the same manner as in Example 2-1 except that the treatment conditions were saturated steam at 210 ° C and 1.4 MPa. This was freeze-dried to obtain a processed reishi product (lyophilized product).
- the processed Ganoderma lucidum obtained in the above Examples 2-1 to 2-3 was physiological saline in a concentration of 250 / zg per mouse. And administered intraperitoneally.
- MM46 tumor-bearing mice to which the same amount of physiological saline alone was administered were used. Twenty-eight days after the subcutaneous inoculation, the tumor was excised and weighed, and the tumor weight of each mouse was compared with the tumor weight of the control mouse as 100%. Measurement results See Table 2.
- the extraction rates of the Kazuno Reishi extracts obtained in Examples 11 to 15 and Comparative Examples 11 to 14 were measured.
- the extraction rate is the ratio of the weight of Kazuno Reishi extract to the total weight of Kazuno Reishi in terms of mass percentage.
- Figure 1 shows the measurement results. It can be seen that the extraction rates of Examples 11 to 15 are higher than the extraction rates of Comparative Examples 1-3 to 1-4.
- Water-soluble—Glucan is one of the components known to have antitumor effects.
- the amount of water-soluble glucan eluted from the processed Ganoderma lucidus products obtained in Examples 1-4 and 2-2 having particularly strong antitumor effects was analyzed.
- the amount of —glucan eluted from the Kazuno Reishi extract obtained in Comparative Example 14 was analyzed.
- the analysis sample was prepared by dissolving Kazuno Reishi extract lg in 40 ml of distilled water and analyzed by an enzymatic method according to a conventional method. That is, the analysis sample was reacted with tamyl in a 0.08 M phosphate buffer, adjusted to pH 7.5 with a NaOH solution, and then reacted with a protease. Thereafter, the pH was adjusted to 4.3 with hydrochloric acid, and amyloglucosidase was reacted. Thereafter, 95% ethanol was added in a four-fold amount to obtain a precipitate (crude j8-glucan fraction).
- FIG. 2 shows the content of water-soluble ⁇ -glucan in the extract obtained from 100 g of Kazuno Reishi.
- the processed reishi product (reishi extract) obtained by the methods of Examples 1-4 and 2-2 shows that more water-soluble mono-glucan was eluted.
- Example 14 it was proved that the water-soluble j8-glucan can be more efficiently eluted by treating the reishi with hot water and then extracting it with hot water.
- a high-temperature and high-humidity heat treatment test apparatus Hisaka Manufacturing Co., Ltd .: HTS 25/1 40-8039
- a steam boiler Moura Kogyo Co., Ltd .: FH-100
- 1.5 kg of Kazuno Reishi used in Example 1-1 was cut into 1 cm pieces, was cut into a SUS316 alloy 12L basket, and the basket was set in a SUS316 alloy heat and pressure resistant container (30 L) and sealed. .
- the air in the container is sent by sending high-temperature, high-pressure saturated steam generated using water (oxygen concentration 0.3 IX gZml) deoxygenated by a deoxygenation device (DOR-1000P, manufactured by Miura Industry Co., Ltd.) for about 1 second.
- a deoxygenation device DOR-1000P, manufactured by Miura Industry Co., Ltd.
- the high-temperature and high-pressure state at 200 ° C and a pressure of 1.4 MPa was maintained for 300 seconds.
- the reactor was opened when the temperature of the reactor reached 80 ° C or lower.
- 24 L of water was added to the steamed product of Kazuno Reishi obtained above, and extraction (autoclave extraction) was performed twice at 121 ° C for 30 minutes.
- the obtained extract was freeze-dried to obtain Kazuno Reishi dried powder.
- the ddY mice (Japan SLC Co., Ltd.) were divided into 5 groups (10 mice per group), and the ddY mice were treated with the three kinds of Kazuno Reishi diet prepared above, a 2.5% control diet and mice. Rats were fed a standard diet AIN-93M only (hereinafter also referred to as a control diet) freely. After breeding for one week, 1 ⁇ 10 6 cells of Sarcomal 80 sarcoma cells were subcutaneously inoculated into the chest of ddY mice to obtain Sarcoma 180 tumor-bearing mice. Sarcoma 180 tumor-bearing mice were continuously fed with the three types of Kazuno Reishi diet prepared above, a 2.5% control diet and a control diet, respectively. Eighteen days after subcutaneous inoculation, the tumor was excised and weighed, and the tumor weight of each mouse was compared with that of the control mouse as 100%. Table 3 shows the measurement results.
- the processed Ganoderma lucidum of the present invention can obtain a high antitumor activity even by oral administration as compared with untreated Ganoderma lucidum.
- Example 11 The Kazuno Reishi used in 1 was subjected to high-temperature and high-pressure steam treatment in the same manner as in Example 3 (steam treatment conditions: 200 ° C, pressurization pressure 1.4 MPa, 5 minutes), and without performing autoclave extraction. After drying and grinding, it is mixed with a standard feed for mice and rats AIN-93M (manufactured by Oriental Yeast Kogyo Co., Ltd.) at a ratio of 0.625% by mass, and is fed with Kazuno Reishi (0.625% Kazuno Reishi). Food).
- Kazuno Reishi (commercially available, from Shandongzhou, China) was crushed with Kazuno Reishi powder at a ratio of 2.5%, a standard diet for mice and rats AIN-93M (Oriental yeast yeast). A feed (hereinafter, also referred to as a 2.5% control diet) was prepared.
- C3H mice (Nippon Charles Riva Co., Ltd.) were divided into 5 groups (15 per group), and the C3H mice were prepared as above with 0.62 5% Kazuno Reishi diet, 2.5% control Food, standard diet for mice and rats Only AIN-93M (hereinafter referred to as control diet) was freely fed.
- control diet 0.62 5% Kazuno Reishi diet, 2.5% control Food, standard diet for mice and rats Only AIN-93M (hereinafter referred to as control diet) was freely fed.
- 2 ⁇ 10 6 cells of MM46 breast cancer cells were subcutaneously inoculated into the mouse inguinal region to obtain MM46 tumor-bearing mice. Twenty-eight days after the subcutaneous inoculation, the tumor was excised and weighed, and the tumor weight of each mouse was compared when the tumor weight of the control mouse was 100%. Table 4 shows the measurement results.
- Anticancer polysaccharides derived from mushrooms such as pharmaceuticals lentinan and krestin, are not used alone but are used in combination with anticancer drugs.
- the combined effect of the high-temperature and high-pressure treated Kazuno Reishi extract and the anticancer chemotherapeutic agent of the present invention was examined.
- MM46 breast cancer cells were subcutaneously inoculated into the inguinal region of C3H mice at 2 ⁇ 10 6 cells each to obtain MM46 tumor-bearing mice.
- One week after subcutaneous inoculation the mice were divided into 6 groups based on the size of the tumor that had developed, and were prepared in Test Example 5.0.156% Kazuno Reishi diet, 0.625% Kazuno Reishi diet, 2.5 % Kazuno Reishi diet, 2.5% control diet, and control diet were each fed freely.
- cyclophosphamide (CY) an anticancer chemotherapeutic agent
- the control group was bred on a control diet, and an equal volume of physiological saline was intraperitoneally administered instead of CY. Twenty-eight days after subcutaneous inoculation, tumors were excised and weighed, and tumors in each mouse were taken assuming that the weight of tumor in control mice was 100%. The tumor weights were compared. Table 5 shows the measurement results.
- a tablet containing the processed product of Reishi was produced by the following method.
- the container is prepared by sending high-temperature, high-pressure saturated steam generated using water (oxygen concentration: 0.3 ⁇ g / ml) deoxygenated by a deoxygenation device (Miura Kogyo Co., Ltd .: DOR-1000P) for about 1 second. After replacing the air inside, a high temperature and high pressure state of 200 ° C and a pressurization pressure of 1.4 MPa was maintained for 300 seconds. After degassing, when the temperature of the reaction vessel reached 80 ° C or lower, the vessel was opened.
- tablets having a diameter of 10 mm and a weight of 300 mg were produced.
- magnesium stearate 0.59 g was added to 99.5 g of the processed reishi product A9 obtained in the same manner as in Example 3, and the mixture was compressed, pulverized, sized, and sieved to obtain granules of 20 to 50 mesh.
- Reishi processed product C was prepared. 0.4 g of maltitol and 0.1 lg of starch were added to the processed Reishi product CI. Og, and the mixture was granulated and sieved to obtain granules of 20 to 50 mesh.
- Lactic acid beverage [Table 14] Composition Parts by weight Milk solids 2 1% fermented milk 1 4.76 Fructose dextrose liquid sugar 1 3.3 1 Pectin 0.50 Cuenoic acid 0.08 Fragrance 0.15 Water 7.11 1 4 Reishi processed product B 0.06
- a reishi product or a reishi product having an excellent antitumor effect can be produced in an industrially advantageous manner. Useful for In particular, it is extremely effective for cancer patients, and its industrial contribution is enormous.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Sustainable Development (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512773A JPWO2005105128A1 (ja) | 2004-04-28 | 2005-04-25 | 霊芝処理物および霊芝加工品の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004134761 | 2004-04-28 | ||
JP2004-134761 | 2004-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005105128A1 true WO2005105128A1 (ja) | 2005-11-10 |
Family
ID=35241436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/007810 WO2005105128A1 (ja) | 2004-04-28 | 2005-04-25 | 霊芝処理物および霊芝加工品の製造方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2005105128A1 (ja) |
TW (1) | TW200536486A (ja) |
WO (1) | WO2005105128A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006282580A (ja) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | キノコ由来の生理活性成分の取得方法 |
JP2006282847A (ja) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | キノコ由来の生理活性成分の取得方法 |
JP2007045713A (ja) * | 2005-08-05 | 2007-02-22 | Iskra Ind Co Ltd | 霊芝胞子抽出物及び霊芝胞子製剤 |
JP2008138195A (ja) * | 2006-11-09 | 2008-06-19 | Mizota Corp | 鹿角霊芝からの有用物質の抽出方法とその装置 |
JP2014090711A (ja) * | 2012-11-07 | 2014-05-19 | Yamato Kanpo Kk | 鹿角霊芝の処理方法、鹿角霊芝処理物及び飲食物 |
CN104872624A (zh) * | 2015-05-08 | 2015-09-02 | 苏州葛家坞生物科技有限公司 | 一种灵芝即食休闲食品的制备方法 |
CN113951356A (zh) * | 2021-10-15 | 2022-01-21 | 上海舒泽生物科技研究所 | 提高免疫力的香菇和灵芝多糖复合压片糖果及其制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107602719B (zh) * | 2017-10-20 | 2020-12-29 | 广东粤微食用菌技术有限公司 | 一种具有显著辅助抗肿瘤活性的灵芝子实体精制多糖及其制备方法和应用 |
CN107722131B (zh) * | 2017-10-20 | 2020-12-29 | 广东粤微食用菌技术有限公司 | 一种具有显著辅助抗肿瘤活性的全灵芝孢子粉精制多糖及其制备方法和应用 |
CN111280287A (zh) * | 2020-03-30 | 2020-06-16 | 陕西科技大学 | 一种具有解酒、护肝功效的羊乳食用菌冰淇淋及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11243908A (ja) * | 1998-03-02 | 1999-09-14 | Shingo Kikuchi | 霊芝(マンネンタケ)から効率良くエキスを抽出する製法 |
JP2001187745A (ja) * | 1999-12-28 | 2001-07-10 | Joyaku Kenkyusho:Kk | 霊芝生理活性エキスおよびそれを用いる健康食品 |
-
2005
- 2005-04-22 TW TW094112843A patent/TW200536486A/zh unknown
- 2005-04-25 WO PCT/JP2005/007810 patent/WO2005105128A1/ja active Application Filing
- 2005-04-25 JP JP2006512773A patent/JPWO2005105128A1/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11243908A (ja) * | 1998-03-02 | 1999-09-14 | Shingo Kikuchi | 霊芝(マンネンタケ)から効率良くエキスを抽出する製法 |
JP2001187745A (ja) * | 1999-12-28 | 2001-07-10 | Joyaku Kenkyusho:Kk | 霊芝生理活性エキスおよびそれを用いる健康食品 |
Non-Patent Citations (1)
Title |
---|
NONAKA Y. ET AL: "Rokkaku Reishi no Koshuyo Seibun ni yoru Th1-Kata Cytokine no Yudo Koka.", THE JAPANESE CANCER ASSOCIATION., vol. 62, 2003, pages 444, XP002994267 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006282580A (ja) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | キノコ由来の生理活性成分の取得方法 |
JP2006282847A (ja) * | 2005-03-31 | 2006-10-19 | Kobayashi Pharmaceut Co Ltd | キノコ由来の生理活性成分の取得方法 |
JP2007045713A (ja) * | 2005-08-05 | 2007-02-22 | Iskra Ind Co Ltd | 霊芝胞子抽出物及び霊芝胞子製剤 |
JP2008138195A (ja) * | 2006-11-09 | 2008-06-19 | Mizota Corp | 鹿角霊芝からの有用物質の抽出方法とその装置 |
JP2014090711A (ja) * | 2012-11-07 | 2014-05-19 | Yamato Kanpo Kk | 鹿角霊芝の処理方法、鹿角霊芝処理物及び飲食物 |
CN104872624A (zh) * | 2015-05-08 | 2015-09-02 | 苏州葛家坞生物科技有限公司 | 一种灵芝即食休闲食品的制备方法 |
CN113951356A (zh) * | 2021-10-15 | 2022-01-21 | 上海舒泽生物科技研究所 | 提高免疫力的香菇和灵芝多糖复合压片糖果及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005105128A1 (ja) | 2008-03-13 |
TW200536486A (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105128A1 (ja) | 霊芝処理物および霊芝加工品の製造方法 | |
KR20030080290A (ko) | 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물 | |
JP2002371002A (ja) | 生理活性大麦エキス、その製造方法、及び該エキスを含む飲食品 | |
KR20160013731A (ko) | 진세노사이드 Rh2와 Rg3의 함량이 증진된 인삼 발효물의 제조 방법 | |
KR20210060864A (ko) | 인삼 잎 기원의 진세노사이드 함유 발효액 및 그 제조 방법 | |
KR102478724B1 (ko) | 감귤 발효 콤부차를 유효성분으로 포함하는 당뇨 또는 심혈관질환 치료용 조성물 | |
JP5144112B2 (ja) | 脳保護剤 | |
CN109527190A (zh) | 黑木耳复合小分子肽粉的制备方法及其应用 | |
JP2012085591A (ja) | ダイエット食品 | |
KR20140105657A (ko) | 오미자 당침 발효물 분말 또는 이의 추출물을 유효성분으로 함유하는 항산화 및 고혈압 치료 또는 예방을 위한 조성물 | |
KR20180042936A (ko) | 치마버섯 분리 균사체 배양액을 유효성분으로 함유하는 숙취해소 및 간질환의 예방 및 치료용 약학조성물 | |
KR102445444B1 (ko) | 안전성을 기반으로 한 고함량의 기능성 성분을 포함하는 발효흑삼 제조 개선 방법 | |
KR101034986B1 (ko) | 혼합 생약추출물을 유효성분으로 함유하는 숙취해소용 조성물 | |
JP2008255057A (ja) | 抗癌剤、抗癌剤の製造方法、及び飲食品 | |
KR101975018B1 (ko) | 인삼열매-목이버섯 균사체 혼합 배양물을 포함하는 콜레스테롤 저하용 조성물 | |
KR101482044B1 (ko) | 하수오 및 생강 발효물을 포함하는 퇴행성 뇌질환 예방 또는 개선용 식품 조성물 및 그 제조방법 | |
JP6251862B2 (ja) | Ace阻害剤 | |
JP6044944B2 (ja) | 新規梅加工品の製造方法及びこれを用いた機能性組成物、食品組成物、医薬組成物 | |
CN112423770A (zh) | 包含酵母提取物的改善糖尿病或增强抗氧化活性的组合物及制备酵母提取物的方法 | |
KR100556683B1 (ko) | 약효가 증강된 파낙스속 식물의 가공 추출물 및 상기추출물로부터 분리된 사포닌 유도체를 함유하는 위장관질환의 예방 및 치료를 위한 조성물 | |
KR20200098224A (ko) | 청귤 추출박 또는 청피 유래의 다당을 포함하는 프리바이오틱스 및 이를 유효성분으로 포함하는 장내 프로바이오틱스 증식 촉진용 조성물 | |
KR101975017B1 (ko) | 인삼열매-홍국 혼합 배양물을 포함하는 콜레스테롤 저하용 조성물 | |
CN109275914A (zh) | 黑木耳多肽功能食用组合物及其制备方法和应用 | |
KR102242002B1 (ko) | 동충하초균사체로 고상발효된 홍삼 추출물을 유효성분으로 함유하는 지방간 질환 예방 또는 치료용 조성물 | |
KR102444884B1 (ko) | 비타민 b1 및 b2를 고함량으로 함유하는 맥주효모 추출물 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006512773 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |